Intranasal INNA-051 for Prevention of COVID-19 in Adults
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults
following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection.
This study will evaluate 2 active dose levels of INNA-051 and placebo.